Literature DB >> 36008791

Characteristics of non-stenotic carotid plaque in embolic stroke of undetermined source compared with cardiogenic embolism: a retrospective cross-sectional observational study.

Lihao Zhang1, Yikun Guo1, Wang Zhou1, Shumin Zhu1, Zhuoyou Chen1, Guanzhong Dong1,2, Yin Cao3,4.   

Abstract

BACKGROUND: Non-stenotic carotid plaque is considered an important etiology of embolic stroke of undetermined source (ESUS). However, only a few previous studies included a negative control group, and the characteristics of non-stenotic carotid plaque in ESUS have yet to be investigated. The objective of this study is to explore the clinical characteristics of ESUS and the correlation between non-stenotic carotid plaque and ESUS.
METHODS: This is a single-center, retrospective cross-sectional observational study conducted to compare differences in clinical information among ESUS, CE, and large-artery atherosclerosis (LAA), as well as the prevalence of non-stenotic carotid plaque and non-stenotic carotid plaque with low echo between patients with ESUS and CE in Changzhou No.2 People's Hospital from January 2020 to January 2022. Ultrasound was used to evaluate the characteristics of non-stenotic carotid plaque and vulnerable carotid plaque was defined as plaque with low echo. The binary logistic regression model was used to analyze the relationship between the characteristics of non-stenotic carotid plaque and ESUS. The receiver-operating characteristic curve was used to evaluate the diagnostic efficiency of the characteristics of non-stenotic carotid plaque for ESUS.
RESULTS: We had a final studying population of 280 patients including 81 with ESUS, 37 with CE, and 162 with LAA. There were no differences in clinical features between ESUS and LAA, but in the comparison of CE and ESUS, there were differences in age, smoking, hypertension, levels of triglyceride, total cholesterol, and low density lipoprotein cholesterol. In ESUS, the prevalence of non-stenotic carotid plaque was more common on the ipsilateral side of stroke than in CE [55 (67.90%) vs. 18 (48.65%), p = 0.046], so was the prevalence of non-stenotic carotid plaque with low echo [38 (46.91%) vs. 5 (13.51%), p < 0.001]. Logistic regression analysis showed that the prevalence of non-stenotic carotid plaque (OR: 4.19; 95% CI: 1.45-12.11; p = 0.008) and the prevalence of non-stenotic carotid plaque with low echo (OR: 5.12; 95% CI: 1.55-16.93; p = 0.007) were, respectively, the independent predictors of ESUS. The results receiver-operating characteristic (ROC) curve showed that the combination of age, hypertension, and ipsilateral non-stenotic carotid plaque with low echo had the best diagnostic efficiency for ESUS (0.811; 95%CI: 0.727-0.896; p < 0.001).
CONCLUSION: Our results suggest that ipsilateral vulnerable non-stenotic carotid plaque is associated with ESUS in anterior circulation infarction.
© 2022. The Author(s).

Entities:  

Keywords:  Cardiogenic embolism; Embolic stroke of undetermined source; Non-stenotic carotid plaque; Ultrasound

Mesh:

Year:  2022        PMID: 36008791      PMCID: PMC9404624          DOI: 10.1186/s12883-022-02846-4

Source DB:  PubMed          Journal:  BMC Neurol        ISSN: 1471-2377            Impact factor:   2.903


Introduction

Embolic stroke of undetermined source (ESUS) refers to the non-lacunar infarct pattern on computed tomography (CT) or magnetic resonance imaging (MRI) without obvious luminal stenosis (vessel stenosis ≥50%) in the arteries supplying the infarct region and significant cardioembolic source. Reportedly, it involves approximately 17% of all ischemic stroke and could be attributed to a variety of causes [1]. Studies have shown that an appreciable incidence of atrial fibrillation (AF) was detected during the follow-up, and the occult AF is considered to be the most common etiology of ESUS [2]. However, the results of studies focusing on anticoagulant therapy in ESUS patients were neutral [3, 4]. Recently, the prevalence of non-stenotic carotid plaques in ESUS patients was found higher on the ipsilateral side than on the contralateral side, suggesting that the non-stenotic carotid plaques might be another cause of ESUS [3, 5]. Ultrasonography is one of the most commonly used techniques in evaluating carotid plaque. Former studies have shown that plaque with low echo is often correlated to the presence of lipid-rich necrotic cores. The plaque with low echo was found in approximately 50% of symptomatic plaques but only 5% of asymptomatic plaques. Additionally, regardless of the degree of stenosis, patients with plaques with low echo had a higher risk of stroke than patients with high-grade stenosis. As a result, the plaque with low echo in ultrasonography indicates plaque vulnerability [6]. The clinical information of ESUS, cardiogenic embolism (CE), and large-artery atherosclerosis (LAA) were compared in this study to see if the risk factors in ESUS are more similar to LAA rather than to CE. This study also used carotid ultrasonography to assess the characteristics of non-stenotic carotid plaque in patients with ESUS and cardiogenic embolism (CE) to confirm the association between the ipsilateral non-stenotic carotid plaques and ESUS and the association is not present in CE.

Materials and methods

Study population

We retrieved data from the stroke center database of Changzhou No.2 People’s Hospital, Jiangsu Province, China. This study was approved by the Clinical Research Ethics Committee of the Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University (2021KY312–01). A written informed consent was obtained from the patients or their legally authorized representatives. All patient information was de-identified. This study was conducted in accordance with the Declaration of Helsinki. Consecutive acute ischemic stroke patients with the diagnosis of LAA, CE, and ESUS from January 2020 to January 2022 were retrospectively enrolled. Patients were included if they met the following criteria: (1) age ≥ 18 years old, (2) unilateral anterior circulation infarction, (3) Necessary assessments were performed for the diagnosis of stroke subtypes such as hematologic screening, brain CT or MRI, 12-lead ECG, ≥24 h dynamic electrocardiogram, precordial echocardiography, extra- and intra-cranial angiography and carotid ultrasonography. Patients were excluded if they (1) undertook thrombectomy, balloon dilatation or stent, (2) had posterior or bilateral infarcts on DWI, (3) were diagnosed as other causes of stroke (such as arteritis, dissection, and vasospasm) or (4) combined with intracranial hemorrhagic disease, central nervous system infections, or tumors. ESUS was identified as: (1) stroke detected by CT or MRI that is not lacunar, (2) absence of extracranial or intracranial atherosclerosis causing ≥50% luminal stenosis in arteries supplying the area of ischemia, (3) no major-risk cardioembolic source of embolism, (4) no other identified specific cause of stroke [7]. Diagnosis for LAA, CE, and other stroke subtypes were made according to the TOAST classification [8]. Two senior neurologists were responsible for the patients’ recruitment, and if there was disagreement, an agreement was reached through discussion.

Assessment of carotid plaques

Characteristics of common and internal carotid plaques in patients with ESUS and CE were assessed using a Philips IE33 duplex ultrasonographic device (USA) and plaque echogenicity was classified into high echo (calcified lesions), mixed echo (combined with calcified and hypoechoic lesions) and low echo (high lipid or hemorrhage lesion). Operators all followed a standard operating method and process. Carotid plaque was defined as minimal intima-media thickness ≥ 1.2 mm. Vulnerable carotid plaque was defined as plaque with low echo [9].

Statistical analysis

Statistical analyses were conducted by SPSS 23.0. Continuous variables in normal distribution were given as mean and SD otherwise as median and interquartile. Pairwise comparisons were performed by the Student’s t test or Mann–Whitney test for continuous variables and Chi square test for categorical variables. Association between ipsilateral non-stenotic carotid plaque and ESUS was analyzed using binary logistic regression. The receiver-operating characteristic (ROC) curve was used to evaluate the diagnostic efficiency of the characteristics of non-stenotic carotid plaque combined with other risk factors for ESUS. P < 0.05 was taken to be statistically significant. Figures were created using GraphPad Prism 9.

Results

Baseline information

A total of 471 patients were enrolled, including 149 ESUS patients, 78 CE patients, and 244 LAA patients. For ESUS group, 46 patients who had posterior or bilateral infarcts and 22 patients who had incomplete information were excluded. For CE group, 30 patients with posterior or bilateral infarcts and 11 patients without complete information were excluded. For LAA group, 70 patients with posterior or bilateral infarcts and 12 patients with incomplete information were excluded. Finally, 280 patients were included for analysis, of whom 81 had ESUS, 37 had CE, and 162 had LAA (Fig. 1).
Fig. 1

The flow chart of the study recruitment

The flow chart of the study recruitment

Differences of risk factors between groups

In comparison to CE patients, ESUS patients were younger (p = 0.001), more likely to be a smoker (40.74% vs. 18.92%, p = 0.02), and had a higher prevalence of hypertension (82.72% vs. 59.46%, p = 0.006). Also, they had a higher level of triglyceride (TG) (p < 0.001), total cholesterol (TCH) (p = 0.027), and low density lipoprotein cholesterol (LDL-C) (p = 0.044). There was no difference in neurological deficit measured using the National Institutes of Health Stroke Scale (NIHSS) between ESUS and CE. During the screening, we found 13 (16.05%) patients in ESUS and 5 (13.51%) patients in CE with non-stenotic intracranial plaque ipsilateral to the stroke site, with no difference (p = 0.722). When comparing ESUS patients with LAA patients, there were no differences in clinical features between the two groups. Since the etiology of LAA is stenosis or occlusion of large arteries, we did not count the plaque in LAA patients. Detailed information can be seen in Table 1.
Table 1

Basic information of patients with anterior circulation stroke in ESUS, CE, and LAA

CharacteristicsnCE (n = 37)ESUS (n = 81)P-valueLAA (n = 162)ESUS (n = 81)P-value
Gender male, n (%)22 (59.46)51 (62.96)0.716a101 (62.35)51 (62.96)0.925a
Age, years, median (IQR)74.0 (64.0–82.5)65.0 (56.0–72.5)0.001b67.0 (57.8–74.0)65.0 (56.0–72.5)0.302b
Smoking, n (%)7 (18.92)33 (40.74)0.020a56 (34.57)33 (40.74)0.346a
Diabetes Mellitus, n (%)10 (27.03)31 (38.27)0.234a72 (44.44)31 (38.27)0.359a
Hypertension, n (%)22 (59.46)67 (82.72)0.006a141 (87.04)67 (82.72)0.366a
Homocysteine, μmol/L, mean ± SD10.97 ± 3.4811.74 ± 7.090.534c11.25 ± 6.3211.74 ± 7.090.588c
Triglyceride, mmol/L, mean ± SD1.03 ± 0.551.56 ± 0.90< 0.001c1.56 ± 1.011.56 ± 0.900.996c
Lipoprotein (a), g/L, mean ± SD0.25 ± 0.190.27 ± 0.240.661c0.32 ± 0.280.27 ± 0.240.165c
Total cholesterol, mmol/L, mean ± SD3.81 ± 0.684.21 ± 0.990.027c4.06 ± 0.934.21 ± 0.990.262c
High density lipoprotein cholesterol, mmol/L, mean ± SD1.15 ± 0.311.07 ± 0.220.177c1.05 ± 0.261.07 ± 0.220.597c
Low density lipoprotein cholesterol, mmol/L, mean ± SD2.24 ± 0.592.55 ± 0.810.044c2.46 ± 0.762.55 ± 0.810.425c
NIHSS score, median (IQR)4.0 (3.0–5.0)3.0 (1.0–5.0)0.107b3.5 (2.0–6.0)3.0 (1.0–5.0)0.095b
With intracranial plaque ipsilateral to the stroke site, n (%)5 (13.51)13 (16.05)0.722a_13 (16.05)_

aPearson’s χ2 test

bMann–Whitney U-test

cStudent’s t-test

Abbreviations: ESUS Embolic stroke of undetermined source, LAA Large-artery atherosclerosis, CE Cardiogenic embolism, NIHSS National Institutes of Health Stroke Scale, IQR Interquartile range, SD Standard deviation

Basic information of patients with anterior circulation stroke in ESUS, CE, and LAA aPearson’s χ2 test bMann–Whitney U-test cStudent’s t-test Abbreviations: ESUS Embolic stroke of undetermined source, LAA Large-artery atherosclerosis, CE Cardiogenic embolism, NIHSS National Institutes of Health Stroke Scale, IQR Interquartile range, SD Standard deviation

Comparisons of ultrasonic findings between ESUS and CE patients

Compared with CE patients, ESUS patients had a higher incidence of non-stenotic carotid plaques on the ipsilateral side of stroke than that on the contralateral side (67.90% vs. 48.65%, p = 0.046). Furthermore, they had a higher incidence of vulnerable ipsilateral non-stenotic carotid plaques than CE patients (46.91% vs. 13.51%, p < 0.001). Detailed information can be seen in Table 2.
Table 2

Characteristics of non-stenotic plaques in patients with anterior circulation stroke in ESUS and CE

CharacteristicsESUS (n = 81)CE (n = 37)P-value
non-stenotic carotid plaque ipsilateral to the stroke site55 (67.90)18 (48.65)0.046a
non-stenotic carotid plaque with low echo ipsilateral to the stroke site38 (46.91)5 (13.51)< 0.001a

aPearson’s χ2 test

Abbreviations: ESUS Embolic stroke of undetermined source, CE Cardiogenic embolism

Characteristics of non-stenotic plaques in patients with anterior circulation stroke in ESUS and CE aPearson’s χ2 test Abbreviations: ESUS Embolic stroke of undetermined source, CE Cardiogenic embolism

Association between characteristics of carotid plaques and ESUS

After adjustment for variables with p < 0.05 in the comparison of ESUS with CE, including age, hypertension, smoking, and hyperlipidemia, the presence of ipsilateral non-stenotic carotid plaque (OR: 4.19; 95% CI: 1.45–12.11; p = 0.008), as well as the presence of ipsilateral non-stenotic carotid plaque with low echo (OR: 5.12; 95% CI: 1.55–16.93; p = 0.007), remained a predictor for ESUS in binary logistic regression analysis (Fig. 2).
Fig. 2

The results of logistic regression analysis. (A) The logistic regression analysis of the model of ipsilateral non-stenotic carotid plaque. (B) The logistic regression analysis of the model of ipsilateral non-stenotic carotid plaque with low echo. Abbreviations: LDL-C, low density lipoprotein cholesterol; TG, triglyceride; TCH, total cholesterol; ESUS, embolic stroke of undetermined source; CE, cardiogenic embolism; OR, odds ratio; CI, confidence interval

The results of logistic regression analysis. (A) The logistic regression analysis of the model of ipsilateral non-stenotic carotid plaque. (B) The logistic regression analysis of the model of ipsilateral non-stenotic carotid plaque with low echo. Abbreviations: LDL-C, low density lipoprotein cholesterol; TG, triglyceride; TCH, total cholesterol; ESUS, embolic stroke of undetermined source; CE, cardiogenic embolism; OR, odds ratio; CI, confidence interval In the ROC analysis, variables with p < 0.05 in the regression analysis were included. Figure 3 showed the results of ROC analysis: combination of age, hypertension, and ipsilateral non-stenotic carotid plaque with low echo (0.811; 95%CI: 0.727–0.896; p < 0.001); combination of age, hypertension, and ipsilateral non-stenotic carotid plaque (0.793; 95%CI: 0.705–0.882; p < 0.001); combination of age and ipsilateral non-stenotic carotid plaque with low echo (0.767; 95%CI: 0.670–0.864; p < 0.001); combination of hypertension and ipsilateral non-stenotic carotid plaque with low echo (0.739; 95%CI: 0.643–0.835; p < 0.001); combination of age and ipsilateral non-stenotic carotid plaque (0.737; 95%CI: 0.633–0.842; p < 0.001); ipsilateral non-stenotic carotid plaque with low echo (0.667; 95%CI: 0.567–0.767; p = 0.004); combination of hypertension and ipsilateral non-stenotic carotid plaque (0.666; 95%CI: 0.557–0.775; p = 0.004); ipsilateral non-stenotic carotid plaque (0.596; 95%CI: 0.484–0.708; p = 0.094), suggesting the presence of ipsilateral vulnerable non-stenotic carotid plaque tended to have good diagnostic efficiency for ESUS.
Fig. 3

The results of receiver-operating curves which shows the characteristics of non-stenotic carotid plaque in prediction of embolic stroke of undetermined source

The results of receiver-operating curves which shows the characteristics of non-stenotic carotid plaque in prediction of embolic stroke of undetermined source

Discussion

This study explored the clinical characteristics of ESUS patients and used ultrasound to examine the features of non-stenotic carotid plaque in ESUS and CE patients. The results showed that the risk factors for ESUS were more similar to those for LAA than for CE and the non-stenotic carotid plaque was more prevalent and vulnerable on the ipsilateral side of stroke in ESUS than in CE. Moreover, the presence of ipsilateral non-stenotic carotid plaque and ipsilateral vulnerable non-stenotic carotid plaque were, respectively, independent risk factors for ESUS. Increasing attention has been paid to the atherosclerotic factors in ESUS. Previous studies have found that ipsilateral non-stenotic carotid plaque is more common in ESUS than in other stroke subtypes. Further research discovered that in ESUS patients, some non-stenotic carotid plaques with vulnerable characteristics, such as large size, intraplaque hemorrhage, and low echo, were more likely to appear on the ipsilateral side of the lesion [10-15]. Although there is no negative control in these researches, these results imply that ipsilateral carotid plaques may be associated with ESUS. In line with these findings, we found that ESUS patients had a higher prevalence of ipsilateral non-stenotic carotid plaque and ipsilateral vulnerable non-stenotic carotid plaque than CE patients. Further, we discovered that the combination of age, hypertension, and ipsilateral vulnerable non-stenotic carotid plaque has the best diagnostic efficiency for ESUS. Our findings, together with the results of the studies mentioned above, may suggest that ipsilateral non-stenotic carotid plaque is a potential cause of ESUS. In addition, recent research suggested that complicated aortic arch, as well as intracranial atherosclerotic plaque, were more frequently detected on the ipsilateral side of ESUS [16, 17]. Lately, the term “supracardiac atherosclerosis” was brought up to summarize all the possible sources of arterial embolism on ESUS [18]. All of the findings support the notion that arterial-to-arterial embolization, rather than hemodynamic disruption, is an important mechanism of ESUS produced by non-stenotic carotid plaque. Clinical investigations have shown that ESUS patients with non-stenotic carotid plaque have a low risk of developing AF or patent foramen ovale (PFO). A pooled analysis of three prospective stroke registries showed that AF was detected in 14.4% of ESUS patients during the follow-up, including 8.5% of patients with the non-stenotic carotid plaque and 19% of patients without [19]. Another larger clinical study demonstrated that only 3.4% of ESUS patients were diagnosed clinically with AF during the trial follow-up period [20]. Similarly, studies have shown that 5–9% of ESUS patients with non-stenotic carotid plaque have PFO [21]. Our study was a cross-sectional study without long-term follow-up and we did not perform transesophageal ultrasonography in the patient screening, the impact of non-stenotic carotid plaque on ESUS might be overestimated. Nevertheless, given the low probability of AF and PFO in ESUS patients, our results still have great clinical significance. Ultrasound was used in our study to identify risk factors for ESUS. Because of its noninvasive character, convenience, and low cost, ultrasound has been widely used in the risk stratification of stroke. In a study that used multimodal ultrasound to investigate plaque risk stratification in patients with asymptomatic carotid stenosis, plaque surface morphology, intraplaque neovascularization grades, and carotid stenosis degree were found to be risk factors for ischemic vascular events [ 22]. Also, a study using doppler ultrasonography to assess global cerebral inflow discovered that individuals with decreased cerebral blood flow were more likely to develop ischemia, providing a novel and simple way for detecting patients at risk of cerebral ischemia [23]. However, ultrasound is used primarily in assessing the echogenicity of plaques and has lower sensitivity for detecting plaque ulceration when compared to CT and MR angiography [6]. Future we could enhance our database with more CT and MR angiography. Our study has the following limitations. First, this study used a single-center database and had a small sample size, which may increase the possibility of selection bias. Second, transesophageal echocardiography and a long-term electrocardiogram were not conducted, which may slightly overestimate the effect of non-stenotic carotid plaque on ESUS.

Conclusion

The clinical characteristics of ESUS were more similar to those of LAA than of CE. Both non-stenotic carotid plaque and vulnerable non-stenotic carotid plaque were more prevalent on the ipsilateral side of ESUS than CE. The presence of ipsilateral vulnerable non-stenotic carotid plaque played an important role in diagnosing ESUS. Our findings support the view that non-stenotic carotid plaque is significantly associated with ESUS. Carotid ultrasonography should be used more broadly to screen for carotid plaque in the ESUS population.
  23 in total

1.  Large but Nonstenotic Carotid Artery Plaque in Patients With a History of Embolic Stroke of Undetermined Source.

Authors:  Teppei Komatsu; Yasuyuki Iguchi; Ayumi Arai; Kenichi Sakuta; Kenichiro Sakai; Yuka Terasawa; Hidetaka Mitsumura; Masato Matsushima
Journal:  Stroke       Date:  2018-12       Impact factor: 7.914

2.  Histological verification of computerised carotid plaque characterisation.

Authors:  N M El-Barghouty; T Levine; S Ladva; A Flanagan; A Nicolaides
Journal:  Eur J Vasc Endovasc Surg       Date:  1996-05       Impact factor: 7.069

3.  Nonstenotic carotid plaque on CT angiography in patients with cryptogenic stroke.

Authors:  Jonathan M Coutinho; Sheldon Derkatch; Alphonse R J Potvin; George Tomlinson; Tim-Rasmus Kiehl; Frank L Silver; Daniel M Mandell
Journal:  Neurology       Date:  2016-07-13       Impact factor: 9.910

4.  Intracranial Atherosclerotic Plaque as a Potential Cause of Embolic Stroke of Undetermined Source.

Authors:  Lin Tao; Xiao-Qiu Li; Xiao-Wen Hou; Ben-Qiang Yang; Cheng Xia; George Ntaios; Hui-Sheng Chen
Journal:  J Am Coll Cardiol       Date:  2021-02-16       Impact factor: 24.094

5.  Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis.

Authors:  George Ntaios; Balakumar Swaminathan; Scott D Berkowitz; Rubens José Gagliardi; Wilfried Lang; James E Siegler; Pablo Lavados; Hardi Mundl; Natan Bornstein; Elena Meseguer; Pierre Amarenco; Brett Cucchiara; Pol Camps-Renom; Konstantinos Makaritsis; Eleni Korompoki; Vasileios Papavasileiou; Joan Marti-Fabregas; Haralampos Milionis; Konstantinos Vemmos; Stuart J Connolly; Robert G Hart
Journal:  Stroke       Date:  2019-08-12       Impact factor: 7.914

6.  Prevalence of nonstenosing, complicated atherosclerotic plaques in cryptogenic stroke.

Authors:  Tobias M Freilinger; Andreas Schindler; Caroline Schmidt; Jochen Grimm; Clemens Cyran; Florian Schwarz; Fabian Bamberg; Jennifer Linn; Maximilian Reiser; Chun Yuan; Konstantin Nikolaou; Martin Dichgans; Tobias Saam
Journal:  JACC Cardiovasc Imaging       Date:  2012-04

Review 7.  Contemporary carotid imaging: from degree of stenosis to plaque vulnerability.

Authors:  Waleed Brinjikji; John Huston; Alejandro A Rabinstein; Gyeong-Moon Kim; Amir Lerman; Giuseppe Lanzino
Journal:  J Neurosurg       Date:  2015-07-31       Impact factor: 5.115

8.  Embolic strokes of undetermined source: the case for a new clinical construct.

Authors:  Robert G Hart; Hans-Christoph Diener; Shelagh B Coutts; J Donald Easton; Christopher B Granger; Martin J O'Donnell; Ralph L Sacco; Stuart J Connolly
Journal:  Lancet Neurol       Date:  2014-04       Impact factor: 44.182

9.  Prevalence and Overlap of Potential Embolic Sources in Patients With Embolic Stroke of Undetermined Source.

Authors:  George Ntaios; Kalliopi Perlepe; Dimitrios Lambrou; Gaia Sirimarco; Davide Strambo; Ashraf Eskandari; Efstathia Karagkiozi; Anastasia Vemmou; Eleni Koroboki; Efstathios Manios; Konstantinos Makaritsis; Konstantinos Vemmos; Patrik Michel
Journal:  J Am Heart Assoc       Date:  2019-07-31       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.